Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Depigmented Extract of Phleum in Local Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Local allergic rhinitis with sensitization to grass pollen~* Skin prick test and serum specific IgE negative to grass pollen.~* Positive Nasal allergen provocation test (NAPT) to grass pollen and/or positive nasal specific IgE to grass pollen.~* Written informed consent~Exclusion Criteria:~* Immunological diseases~* Heart diseases that limit the use of adrenaline. For example, severe hypertension or treatment with beta-blockers.~* Treatment with beta-blockers~* Severe psychological disorders~* Severe atopic dermatitis~* FEV1 \< 70% of reference value after treatment~* Hypersensitivity or intolerance to excipients and / or medication trial.~* Failure to adequately perform diagnostic tests or treatment.~* Sensitization to other allergens (perennial or seasonal) with clinical relevance for the subject and that may interfere in the evaluation of the response.~* Immunotherapy in the 5 years prior to their inclusion in the study.~* Pregnant women or at risk of pregnancy and lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- DEPIGOID phleum (Type: ACTIVE_COMPARATOR): The active treatment arm receive active phleum pollen immunotherapy (Depigoid 100% phleum). Depigmented and polymerized allergen extract of Phleum pollen for subcutaneous injection.
- DEPIGOID Placebo & DEPIGOID Phleum (Type: PLACEBO_COMPARATOR): This arm receive DEPIGOID Placebo during the first year, and DEPIGOID Phleum during the second year of study.~DEPIGOID Placebo contains the same composition as in the active DEPIGOID Phleum with the only difference being the exclusion of the phleum pollen allergen extract.

Based on this trial design, predict the completion outcome and termination type (if applicable).